Who owns First Tracks Biotherapeutics, Inc. (TRAX)? Elite investor 13F holders
2 tracked elite investors reported holding First Tracks Biotherapeutics, Inc as of 2026-09-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | FIRST TRACKS BIOTHERAPEUTICS | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 1422881.00 USD | 40149.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | FIRST TRACKS BIOTHERAPEUTICS | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 1513288.00 USD | 42700.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.